Showing 19 of 19 recruiting trials for “acute-biphenotypic-leukemia”
A Study of Revumenib and Mezigdomide in People With Leukemia
👨⚕️ Eytan Stein, MD, Memorial Sloan Kettering Cancer Center📍 10 sites📅 Started Jan 2026View details ↗
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
👨⚕️ Filippo Milano, MD, PhD, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Sep 2025View details ↗
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
👨⚕️ Ann Dahlberg, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Jul 2024View details ↗
Venetoclax Combined With Azactidine in the Treatment of ALAL
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
👨⚕️ Margaret MacMillan, University of Minnesota Masonic Cancer Center📍 1 site📅 Started May 2023View details ↗
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
👨⚕️ Mary-Beth M. Percival, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Feb 2022View details ↗
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
👨⚕️ Marie Bleakley, Fred Hutch/University of Washington Cancer Consortium📍 10 sites📅 Started Aug 2019View details ↗
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
👨⚕️ Timothy Olson, MD, PhD, Children's Hospital of Philadelphia📍 1 site📅 Started Mar 2019View details ↗
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
👨⚕️ John Perentesis, MD, Children's Hospital Medical Center, Cincinnati📍 1 site📅 Started Dec 2018View details ↗
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Familial Investigations of Childhood Cancer Predisposition
👨⚕️ Kim E. Nichols, MD, St. Jude Children's Research Hospital📍 1 site📅 Started Apr 2017View details ↗
Personalized NK Cell Therapy in CBT
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →